Tildrakizumab
Products Tildrakizumab was approved as an injectable in the United States and EU in 2018 and in many countries in 2019 (ilumetri). Structure and properties Tildrakizumab is a humanized IgG1/k monoclonal antibody with an approximate molecular mass of 147 kDa. It is produced by biotechnological methods. Effects Tildrakizumab (ATC L04AC17) has immunosuppressive and anti-inflammatory properties. … Tildrakizumab